Last reviewed · How we verify

NCT04612322: MICRO

MICRO: a Registry Study in Patients With Microvascular Angina

Recruiting now Last updated 31 March 2022
What this trial tests

trial testing Assessment of microvascular function with intracoronary hemodilution in Microvascular Disease in 1,000 participants. Currently enrolling.

Timeline
10 October 2020
Primary endpoint
10 October 2024
10 October 2029

Quick facts

Lead sponsorJohannes Gutenberg University Mainz
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,000
Start date10 October 2020
Primary completion10 October 2024
Estimated completion10 October 2029
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Johannes Gutenberg University Mainz

Who can join

Adults 18 to 85, any sex, with Microvascular Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The evidence above demonstrates that microvascular dysfunction is an important determinant of patient prognosis, which however remains poorly classified. Given the high burden of disease and the severity of the functional impairment in these patients, the lack of a clear definition for this disease has a potentially large clinical importance. It is important to better describe the phenotype of these patients, identify the predictors of prognosis, and determine the impact of diagnosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Johannes Gutenberg University Mainz trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04612322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing